Table 2.
Network meta-analysis: time to CDMS
| Drug | SUCRA | IFN β-1a 44 μg SC thrice weekly | IFN β-1b 250 μg SC every other day | IFN β-1a 30 μg IM weekly | Glatiramer 20 mg daily | Placebo |
|---|---|---|---|---|---|---|
| IFN β-1a 44 μg SC thrice weekly | 0.70 | 0.96 (0.56, 1.65) | 0.93 (0.56, 1.55) | 0.87 (0.51, 1.50) | 0.48 (0.31, 0.74) | |
| IFN β-1b 250 μg SC every other day | 0.68 | 0.97 (0.63, 1.50) | 0.91 (0.57, 1.45) | 0.50 (0.36, 0.70) | ||
| IFN β-1a 30 μg IM weekly | 0.62 | 0.94 (0.61, 1.45) | 0.52 (0.39, 0.68) | |||
| Glatiramer 20 mg daily | 0.5 | 0.55 (0.40, 0.76) | ||||
| Placebo | 0 |
Findings are expressed as HR (95% CI)